Skip to main content
. 2022 Jul 3;307(3):927–935. doi: 10.1007/s00404-022-06515-2

Table 2.

Progression-free survival (PFS) and overall survival (OS) stratified by histopathological subtype

Histopathological subtype PFS [months] (95% CI) OS [months] (95% CI) 5-year OS Rate
LMS 15 (7.7–22.3) 43 (25.7–60.3) 29.0% ± 8.0%
LG-ESS 38 (9.3–66.7) 150 (83.4–217.1) 69.0% ± 18.0%
HG-ESS 5 (0–23.6) 6 (0–29.5)

95% Confidence Interval

LMS Leiomyosarcoma, LG-ESS low-grade endometrial stromal sarcoma, HG-ESS high-grade ESS, UUS undifferentiated uterine sarcoma